Close Menu
March 25, 2021
Sponsored by
Foundation Medicine

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

GenomeWebinar

Medical Director, Precision Medicine;
Geriatric Oncology Consortium

Chief, Precision Health and Genomics,
Intermountain Healthcare

Research Scientist, Personalized Medicine Specialist,
DeBartolo Family Personalized Medicine Institute, H. Lee Moffitt Cancer Center

Co-Director, Oncology Precision Medicine Program,
Aurora Health Care

Lead Variant Scientist,
Intermountain Healthcare

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

The application of comprehensive genomic profiling (CGP) in patients with metastatic solid tumors aims to identify therapeutic options that were not otherwise evident with standard workup. However, CGP -- even when it analyzes patient samples against 500+ potential mutations — does not always identify an actionable target.  In these cases, clinicians still need to develop a care plan based on best evidence and individual patient goals.

Our panel will discuss several of these cases in detail and recommend next steps.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

About The Series

The Virtual Molecular Tumor Board Series is an interactive and educational online program intended to highlight the key role that molecular tumor boards play in implementing precision oncology.

The series will underscore the collaborative nature of genomic medicine by assembling a multidisciplinary panel of experts who will meet virtually for four one-hour sessions. In each session, the panel will review the genomic and clinical evidence for anonymized patients who have had their tumors sequenced as part of clinical management. The panel will discuss each case and recommend a course of treatment.

Precision Oncology News would like to thank Clariifi for assistance in planning and executing this educational webinar series.


Sponsored by

The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.

The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.

In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

Jan
26
Sponsored by
LGC, Biosearch Technologies

Reduced representation next-generation sequencing (NGS) methods are driving understanding of both physical and structural variation in all species.

Jan
28
Sponsored by
Sophia Genetics

This webinar discusses how the University of Michigan has implemented a new next-generation sequencing (NGS) capture-based solution to assess myeloid malignancies while minimizing required laboratory resources. 

Feb
11
Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
17
Sponsored by
BioLegend

Host immune responses play a central role in controlling SARS-CoV-2 infection, but they remain incompletely characterized and understood.